ISB 1342

· Ichnos Sciences SA

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ISB 1342, covering 2024-06-13 to 2024-06-13. Get the full timeline:

Most recent: Clinical Trial Update: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma [Phase 1]